The pharmaceutical world is seeing a major shift in diabetes treatment with the emergence of GLP-1 patches. These patches offer a seemingly more convenient alternative to subcutaneous administrations of GLP-1 receptor agonists, minimizing the need for daily needle pokes. The technology delivers t